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Objective/background: ‘‘The captain of all these men of death”, is the apt sobriquet for the
age-old disease tuberculosis (TB). Despite the availability of many drugs, cases of increasing
resistance in the forms of multi-drug and extensively drug-resistant TB and persistence
[characteristic ofMycobacterium tuberculosis (MTB)] make the eradication of TB a nightmare.
Approval of bedaquiline by the Food and Drug Administration focused attention on quino-
line scaffolds for development of new anti-TB agents. Lysine e-aminotransferase (LAT) in
MTB plays a pivotal role in regulating amino acid synthesis, which in turn affects mycobac-
terial persistence. Here, developed quinoline inhibitors that targeted LATwith an objective
to eliminate dormant forms of mycobacterium.
Methods: Using e-pharmacophore approaches, quinolone (PBD: 2CJD) leads were found to
inhibit lysine binding to LAT. To investigate structural activity relationships, 21 analogues
were synthesized and characterized based on the identified lead molecules.
Results: Among the derivatives, N-(pyridin-2-yl methyl)-2-(4-(quinolin-4-yl) piperazin-1-yl)
acetamide was identified as a potent molecule, with an IC50 for LAT of 1.04 lM. In
nutrient-starved and zebra fish models, this molecule exhibited logarithmic reductions
of 2.1- and 2.2-fold, respectively, at a concentration of 10 lg/mL. The compound also
exhibited good activity against persistent forms of mycobacteria (biofilm model), showing
logarithmic reduction of 2.8-fold. Additionally, the hit molecule showed concentration-
dependent kill kinetics against dormant forms of mycobacteria, and were devoid of
cytotoxicity against RAW cell lines 264.7 at concentrations of 50 lM.
Conclusion: Our results indicated that the hit molecule showed activity against both active
and persistent forms of infection, which is ideal for new anti-TB agents. This molecule
requires further pharmacokinetic and dynamic screening for development as new drug
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